

---

# Contents

## Part I Generators

|  |    |
|--|----|
| <b><math>^{68}\text{Ge}/^{68}\text{Ga}</math> Generators: Past, Present, and Future</b> . . . . .              | 3  |
| 1 Introduction. . . . .  | 4  |
| 2 The Early Years (1960–1970): The Dawn of $^{68}\text{Ga}$ . . . . .  | 5  |
| 2.1 Further Generator Developments: $\text{Al}_2\text{O}_3$ -Based<br>EDTA-Eluted Generators. . . . .          | 6  |
| 2.2 $^{68}\text{Ga}$ -EDTA: The PET Pharmaceutical, Development<br>of Positron Scintillation Cameras . . . . . | 8  |
| 3 Hibernating $^{68}\text{Ga}$ Medical Applications, but New<br>Chemistry Ahead. . . . .                       | 10 |
| 4 Commercial “Ionic” Generators . . . . .  | 11 |
| 5 Current State/Outlook. . . . .   | 14 |
| References . . . . .   | 15 |

## Overview and Perspectives on Automation Strategies

|   |    |
|---|----|
| <b>in <math>^{68}\text{Ga}</math> Radiopharmaceutical Preparations</b> . . . . .                | 17 |
| 1 Introduction. . . . .   | 18 |
| 2 Approach to Automation: Considerations on $^{68}\text{Ga}$ Radiolabeling<br>Process . . . . . | 19 |
| 3 Modules for $^{68}\text{Ga}$ Radiopharmaceuticals. . . . .                                    | 21 |
| 3.1 Classification and Characteristics of Automated Systems . . . .                             | 21 |
| 3.2 Automation and Regulatory Aspects . . . . .   | 27 |
| 4 Perspectives . . . . .  | 28 |
| References . . . . .  | 30 |

## Post-Processing via Cation Exchange Cartridges:

|   |    |
|---|----|
| <b>Versatile Options.</b> . . . .                                       | 33 |
| 1 Introduction. . . . .   | 34 |
| 2 The Initial Cation Exchange-Based Post-Purification Concept . . . . . | 35 |

|   |   |    |
|---|---|----|
| 3 | Combined Cation and Anion Exchange-Based Post-Processing . . . . .                        | 36 |
| 4 | Post-Processing Towards Nonaqueous Systems for Labeling<br>Lipophilic Compounds . . . . . | 38 |
| 5 | Instant Quantification of Generator $^{68}\text{Ge}$ Breakthrough. . . . .                | 39 |
| 6 | Conclusions. . . . .  | 41 |
|   | References . . . . .  | 41 |

### **$^{68}\text{Ga}$ Generator Integrated System:**

|     |  |           |
|-----|--|-----------|
|     | <b>Elution–Purification–Concentration Integration . . . . .</b>  | <b>43</b> |
| 1   | Introduction. . . . .  | 44        |
| 2   | Nuclear Characteristics and Radioactive Transformation<br>Equilibrium . . . . .  | 50        |
| 3   | $^{68}\text{Ge}/^{68}\text{Ga}$ Separation and $^{68}\text{Ga}$ Generator. . . . .   | 52        |
| 3.1 | Nanocrystalline Ceramic Structure Sorbent Used<br>for Chromatographic $^{68}\text{Ge}/^{68}\text{Ga}$ Separation . . . . .         | 52        |
| 3.2 | $^{68}\text{Ga}$ Generator Setup . . . . .   | 55        |
| 3.3 | Generator Operation and Specification . . . . .  | 56        |
| 3.4 | $^{68}\text{Zn}^{2+}$ Formation and Its Influence on Coordination<br>Chemistry of $^{68}\text{Ga}$ -Radiolabeling . . . . .        | 61        |
| 4   | Post-Elution Purification–Concentration of $^{68}\text{Ga}$ Eluate . . . . .   | 64        |
| 4.1 | Salt-Form Cationic Exchange Resin-Based<br>Purification–Concentration Method. . . . .  | 64        |
| 4.2 | Automation Process and Setup of $^{68}\text{Ga}$ Radioisotope<br>Generator Integrated System (RADIGIS- $^{68}\text{Ga}$ ). . . . . | 65        |
| 4.3 | Basic/Acidic $^{68}\text{Ga}$ Eluates and Their Radiolabeling . . . . .  | 68        |
| 4.4 | Performance of $^{68}\text{Ga}$ Generator and $^{68}\text{Ga}$ Radioisotope<br>Generator Integrated System . . . . .               | 68        |
| 5   | Quality Evaluation Experiments: Quality Control Protocols<br>and Radiolabeling Efficacy Evaluation . . . . .                       | 69        |
| 5.1 | Quality Evaluation of $^{68}\text{Ga}$ Solution . . . . .  | 69        |
| 5.2 | Operation Performance Assessment of Ga-68<br>Generator Systems . . . . .   | 73        |
|     | References . . . . .   | 73        |

### **Purification and Labeling Strategies for $^{68}\text{Ga}$ from $^{68}\text{Ge}/^{68}\text{Ga}$ Generator Eluate.**

|     |   |           |
|-----|---|-----------|
|     | <b>Purification and Labeling Strategies for <math>^{68}\text{Ga}</math> from <math>^{68}\text{Ge}/^{68}\text{Ga}</math> Generator Eluate. . . . .</b> | <b>77</b> |
| 1   | Introduction. . . . .   | 78        |
| 1.1 | History . . . . .   | 78        |
| 1.2 | Current State . . . . .   | 78        |
| 1.3 | Basic Methods . . . . .   | 79        |
| 2   | Combined Cationic Anionic Purification of $^{68}\text{Ge}/^{68}\text{Ga}$ Generator<br>Eluate for Labeling of Fragile Peptides and Proteins . . . . . | 80        |
| 2.1 | Aim . . . . .   | 80        |
| 2.2 | Description . . . . .   | 80        |

|     |   |    |
|-----|---|----|
| 2.3 | Advantages . . . . .  | 81 |
| 2.4 | Example: Synthesis of $^{68}\text{Ga}$ -BPAMD . . . . .   | 81 |
| 3   | A New Highly Efficient NaCl-Based Cationic $^{68}\text{Ge}/^{68}\text{Ga}$<br>Generator Eluate Purification: The Basis for Effective<br>$^{68}\text{Ga}$ Labeling . . . . . | 83 |
| 3.1 | Aim . . . . .   | 83 |
| 3.2 | Labeling Strategy . . . . .   | 84 |
| 3.3 | Description of the Method . . . . .   | 84 |
| 3.4 | Results . . . . .   | 85 |
|     | References . . . . .  | 86 |
|     | <b><math>^{67}\text{Ga}</math> and <math>^{68}\text{Ga}</math> Purification Studies: Preliminary Results.</b> . . . . .   | 89 |
| 1   | Introduction. . . . .   | 90 |
| 2   | Materials and Methods . . . . .   | 91 |
| 2.1 | $^{68}\text{Ge}/^{68}\text{Ga}$ Generator and $^{67}\text{Ga}$ . . . . .  | 91 |
| 2.2 | Materials . . . . .   | 91 |
| 2.3 | Water Purification . . . . .  | 91 |
| 2.4 | $^{68}\text{Ga}$ Purification on Cation Exchange Resin . . . . .  | 91 |
| 2.5 | $^{67}\text{Ga}/^{68}\text{Ga}$ Purification: Isopropyl Ether Extraction System . . . . .   | 92 |
| 3   | Results and Discussion . . . . .  | 93 |
| 3.1 | $^{68}\text{Ge}/^{68}\text{Ga}$ Generator Performance . . . . .   | 93 |
| 3.2 | Water Purification . . . . .  | 93 |
| 3.3 | $^{67}\text{Ga}/^{68}\text{Ga}$ Purification on Cation Exchange Resin . . . . .   | 93 |
| 3.4 | $^{67}\text{Ga}/^{68}\text{Ga}$ Purification Using Isopropyl Ether<br>Extraction System. . . . .  | 94 |
| 4   | Conclusion . . . . .  | 96 |
|     | References . . . . .  | 96 |

## Part II Radiochemistry and Radiopharmacy

|     |  |     |
|-----|--|-----|
|     | <b>The Diversity of <math>^{68}\text{Ga}</math>-Based Imaging Agents</b> . . . . . | 101 |
| 1   | Introduction. . . . .  | 102 |
| 2   | Targeted Imaging. . . . .  | 105 |
| 2.1 | Imaging Somatostatin Receptors. . . . .  | 106 |
| 2.2 | Imaging Human Epidermal Growth Factor Receptor<br>(HER) Family . . . . .           | 108 |
| 2.3 | Imaging Angiogenesis . . . . .   | 111 |
| 2.4 | Antisense Oligonucleotide-Based Tracers . . . . .                                  | 112 |
| 3   | Pretargeted Imaging . . . . .  | 113 |
| 4   | Nontargeted Imaging . . . . .  | 115 |
| 5   | Low-Molecular-Weight Imaging Agents . . . . .                                      | 116 |
| 6   | Further Examples of Diverse Applications of $^{68}\text{Ga}$ . . . . .             | 117 |
| 7   | Conclusions. . . . .   | 117 |
|     | References . . . . .   | 117 |

|  |     |
|--|-----|
| <b>Nanoparticles and Phage Display Selected Peptides for Imaging and Therapy of Cancer</b> . . . . .   | 133 |
| 1 Introduction. . . . .  | 134 |
| 1.1 Biomarkers . . . . .   | 134 |
| 2 Nanoparticles. . . . .   | 136 |
| 2.1 Gold Radioisotope Properties . . . . .   | 137 |
| 2.2 Gum Arabic Gold Nanoparticles. . . . .   | 137 |
| 2.3 Epigallocatechin-Gallate Gold Nanoparticles . . . . .  | 138 |
| 2.4 Bombesin Gold Nanoparticles . . . . .  | 139 |
| 2.5 DTDTPA Gold Nanoparticles for Molecular Imaging . . . . .  | 140 |
| 2.6 Alpha-Emitting Sequestering Nanoparticles . . . . .  | 141 |
| 3 Phage Display . . . . .  | 142 |
| References . . . . .   | 146 |
| <br><b>“Click”-Cyclized <sup>68</sup>Ga-Labeled Peptides for Molecular Imaging and Therapy: Synthesis and Preliminary In Vitro and In Vivo Evaluation in a Melanoma Model System</b> . . . . . | 149 |
| 1 Introduction. . . . .  | 150 |
| 1.1 Targeted Peptides for Molecular Imaging and Therapy . . . . .  | 150 |
| 1.2 Cyclized Melanocyte Stimulating Hormone . . . . .  | 152 |
| 2 Experimental . . . . .   | 154 |
| 2.1 Chemicals and Reagents . . . . .   | 154 |
| 2.2 Peptide Synthesis . . . . .  | 154 |
| 2.3 In Vitro Competitive Binding Assay . . . . .   | 157 |
| 2.4 Radiochemistry . . . . .   | 157 |
| 2.5 Serum Stability Assay . . . . .  | 158 |
| 2.6 In Vivo PET Imaging and Biodistribution Studies . . . . .  | 159 |
| 3 Results . . . . .  | 160 |
| 3.1 Peptide Synthesis . . . . .  | 160 |
| 3.2 Radiolabeling . . . . .  | 161 |
| 3.3 In Vitro Competitive Binding Assays . . . . .  | 161 |
| 3.4 Serum Stability . . . . .  | 162 |
| 3.5 In Vivo Biodistribution and Imaging . . . . .  | 164 |
| 4 Discussion. . . . .  | 164 |
| 4.1 Click Cyclizations and Peptide Synthesis . . . . .   | 164 |
| 4.2 In Vitro Evaluation . . . . .  | 168 |
| 4.3 In Vivo Biodistributions and PET Imaging . . . . .   | 169 |
| 5 Summary and Conclusions . . . . .  | 171 |
| References . . . . .   | 172 |
| <br><b>Early Experience with <sup>68</sup>Ga-DOTATATE Preparation</b> . . . . .  | 177 |
| 1 Introduction. . . . .  | 178 |
| 2 Materials and Methods . . . . .  | 180 |
| 2.1 DOTA-Tyr <sup>3</sup> -Octreotate . . . . .  | 180 |

|      |   |     |
|------|---|-----|
| 2.2  | $^{68}\text{Ge}/^{68}\text{Ga}$ Generator . . . . .       | 180 |
| 2.3  | $^{68}\text{Ga}$ Radiolabeling . . . . .                  | 181 |
| 2.4  | Scan Procedure . . . . .                                  | 181 |
| 3    | Results and Discussion . . . . .                          | 181 |
| 3.1  | Generator Elution Profile . . . . .                       | 181 |
| 3.2  | Post-Elution Processing . . . . .                         | 181 |
| 3.3  | Radiolabeling . . . . .                                   | 182 |
| 3.4  | Loss of Radioactivity During Radiolabeling . . . . .      | 183 |
| 3.5  | Clinical Imaging . . . . .                                | 183 |
| 3.6  | Patient Complaints . . . . .                              | 183 |
| 3.7  | Regulatory Requirement for Routine Clinical Use . . . . . | 184 |
| 3.8  | Number of Cases . . . . .                                 | 185 |
| 3.9  | Future Directions . . . . .                               | 185 |
| 3.10 | Lessons Learnt . . . . .                                  | 186 |
| 4    | Conclusion . . . . .                                      | 186 |
|      | References . . . . .                                      | 186 |

## **$^{68}\text{Ga}$ -Radiopharmaceuticals for PET Imaging of Infection and Inflammation . . . . .**

|     |   |     |
|-----|---|-----|
|     |   | 189 |
| 1   | Introduction . . . . .  | 191 |
| 2   | Overview on Infection Imaging . . . . .   | 193 |
| 2.1 | Labeled Leukocytes for Imaging Infection . . . . .  | 193 |
| 2.2 | Labeled Antibiotics for Infection Imaging . . . . .   | 193 |
| 2.3 | $^{67}\text{Ga}$ -Citrate for Infection Imaging . . . . .   | 194 |
| 3   | Difference Between $^{67}\text{Ga}$ -SPECT and $^{68}\text{Ga}$ -PET . . . . .  | 195 |
| 3.1 | Production of $^{67}\text{Ga}$ and Pure $^{68}\text{Ga}$ . . . . .  | 195 |
| 3.2 | Development of $^{68}\text{Ga}$ Chemistry . . . . .   | 196 |
| 3.3 | Mechanism of Cellular Uptake of Ga-Citrate . . . . .  | 197 |
| 4   | Application of $^{68}\text{Ga}$ -Radiopharmaceuticals for Infection Imaging . . . . .   | 198 |
| 4.1 | Biodistribution of $^{67}\text{Ga}/^{68}\text{Ga}$ -Citrate in Normal Rats and Humans . . . . .   | 198 |
| 4.2 | $^{68}\text{Ga}$ -Citrate PET for Imaging <i>Staph A</i> Infection in an Animal Model . . . . .   | 200 |
| 4.3 | $^{68}\text{Ga}$ -Citrate for Diagnostic PET Imaging of Osteomyelitis and Follow-Up Treatment . . . . .   | 200 |
| 4.4 | $^{68}\text{Ga}$ -Citrate PET/CT for Imaging of Discitis, Cellulitis, and Abscess . . . . .   | 204 |
| 4.5 | $^{68}\text{Ga}$ -Apo-Transferrin ( $^{68}\text{Ga}$ -TF) for PET Imaging of Bacterial Infection . . . . .  | 206 |
| 4.6 | Comparison of $^{68}\text{Ga}$ -Chloride and $^{18}\text{F}$ -FDG for PET Imaging of Osteomyelitis and Human Pancreatic Adenocarcinoma Xenografts in Rats . . . . . | 209 |
| 5   | Evaluation of $^{99\text{m}}\text{Tc}$ - and $^{68}\text{Ga}$ -Glucosamine for Imaging Inflammatory Arthritis . . . . .   | 211 |

|      |   |            |
|------|---|------------|
| 5.1  | Chemical Structures of Glucose Analogs and Synthesis of $^{99m}\text{Tc}$ -Labeled Deoxyglucosamine . . . . .   | 211        |
| 5.2  | Synthesis of $^{68}\text{Ga}$ -Glucosamine and Preliminary Results . . . . .  | 213        |
| 6    | Conclusion . . . . .  | 213        |
|      | References . . . . .  | 214        |
|      | <b><math>^{68}\text{Ga}</math>-Labeled Bombesin Analogs for Receptor-Mediated Imaging . . . . .</b>   | <b>221</b> |
| 1    | Introduction. . . . .   | 223        |
| 2    | Bombesin Receptors and Their Ligands . . . . .  | 225        |
| 3    | Targeted Approach to Receptor-Mediated Imaging . . . . .  | 229        |
| 3.1  | Why Bombesin Receptor-Mediated Imaging?. . . . .  | 229        |
| 3.2  | Gallium Radiometal . . . . .  | 237        |
| 3.3  | Chelating Systems . . . . .   | 239        |
| 4    | Special Focus on Gallium-Labeled Bombesin Analogs . . . . .   | 242        |
| 5    | Conclusion . . . . .  | 245        |
|      | References . . . . .  | 246        |
|      | <b>A Novel <math>^{68}\text{Ga}</math>-Labeled Pterioic Acid-Based PET Tracer for Tumor Imaging via the Folate Receptor . . . . .</b>   | <b>257</b> |
| 1    | Introduction. . . . .   | 258        |
| 2    | Results and Discussion . . . . .  | 260        |
| 2.1  | Synthesis . . . . .   | 260        |
| 2.2  | Radiolabeling and In Vitro Studies . . . . .  | 260        |
| 3    | Conclusion . . . . .  | 262        |
| 4    | Experimental . . . . .  | 263        |
| 4.1  | Benzyl- <i>N</i> -(2-hydroxyethyl)carbamate . . . . .   | 263        |
| 4.2  | <i>N</i> -Benzyloxycarbonyl-2-bromoethylamine . . . . .   | 263        |
| 4.3  | 1-( <i>N</i> -Benzyloxycarbonyl-ethylamine)-1,4,7,10-tetraazacyclododecane . . . . .  | 264        |
| 4.4  | 1-( <i>N</i> -Benzyloxycarbonyl-ethylamine)-4,7,10-tris( <i>tert</i> -butyl-acetate)-1,4,7,10-tetraaza-cyclododecane . . . . .  | 264        |
| 4.5  | 1-(Aminoethyl)-4,7,10-tris( <i>tert</i> -butyl-acetate)-1,4,7,10-tetraazacyclododecane . . . . .  | 264        |
| 4.6  | <i>tert</i> -Butyl 2,2',2''-(10-(2-(4-( <i>N</i> -(((dimethylamino)methyleneamino)-4-oxo-3,4-dihydropteridin-6-yl)methyl)formamido)benzamido)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate . . . . . | 265        |
| 4.7  | 2,2',2''(10-(2-(4-((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methylamino)benzamido)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid . . . . .   | 265        |
| 4.8  | Radiolabeling . . . . .   | 266        |
| 4.9  | Stability Studies . . . . .   | 266        |
| 4.10 | Lipophilicity Assay . . . . .   | 266        |
|      | References . . . . .  | 266        |

|   |            |
|---|------------|
| <b>Measurement of Protein Synthesis: In Vitro Comparison of <math>^{68}\text{Ga}</math>-DOTA-Puromycin, <math>[\text{}^3\text{H}]</math>Tyrosine, and 2-Fluoro-<math>[\text{}^3\text{H}]</math>tyrosine . . . . .</b> | <b>269</b> |
| 1 Introduction. . . . .   | 271        |
| 2 Methods . . . . .   | 272        |
| 2.1 Equipment and Reagents . . . . .  | 272        |
| 2.2 $^{68}\text{Ga}$ Production . . . . .   | 273        |
| 2.3 Synthesis of DOTA-NHC <sub>6</sub> -dC-Puromycin (DOTA-Pur). . . . .  | 273        |
| 2.4 $^{68}\text{Ga}$ -Labeling of DOTA-Pur . . . . .  | 274        |
| 2.5 In Vitro Studies . . . . .  | 274        |
| 2.6 In Vitro Uptake and Protein Incorporation. . . . .  | 274        |
| 2.7 Inhibition of $^{68}\text{Ga}$ -DOTA-Pur, $[\text{}^3\text{H}]$ Tyrosine, and 2-Fluoro- $[\text{}^3\text{H}]$ tyrosine Incorporation into Proteins. . . . .   | 275        |
| 2.8 Statistical Analysis . . . . .  | 276        |
| 3 Results . . . . .   | 276        |
| 3.1 Synthesis of DOTA-NHC <sub>6</sub> -dC-Puromycin . . . . .  | 276        |
| 3.2 $^{68}\text{Ga}$ -Labeling of DOTA-Pur . . . . .  | 276        |
| 3.3 In Vitro Uptake and Protein Incorporation. . . . .  | 276        |
| 3.4 Inhibition of Protein Synthesis . . . . .   | 277        |
| 3.5 $\mu\text{PET}$ Imaging in Tumor-Bearing Rats . . . . .   | 278        |
| 4 Discussion. . . . .   | 280        |
| 5 Conclusions. . . . .  | 282        |
| References . . . . .  | 282        |
| <b>Hypoxia Imaging Agents Labeled with Positron Emitters . . . . .</b>  | <b>285</b> |
| 1 Introduction. . . . .   | 286        |
| 2 Hypoxia . . . . .   | 286        |
| 3 Why Is Detection of Tumor Hypoxia Important? . . . . .  | 286        |
| 4 Nature of an Ideal Hypoxia Imaging Agent for Hypoxia Imaging . . . . .  | 288        |
| 5 Nitroimidazole as Hypoxic Agent . . . . .   | 288        |
| 6 Copper(II)-Diacetyl-bis( <i>N</i> <sup>4</sup> -methylthiosemicarbazone) (Cu-ATSM) as Hypoxic Agent . . . . .   | 293        |
| 7 Retention of Radiolabeled Compounds in EMT6 Cells. . . . .  | 295        |
| 8 Conclusions. . . . .  | 296        |
| References . . . . .  | 296        |
| <b><math>^{177}\text{Lu}/^{90}\text{Y}</math> Intermediate-Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation . . . . .</b>   | <b>301</b> |
| 1 Introduction. . . . .   | 302        |
| 2 Materials and Methods . . . . .   | 304        |
| 2.1 Conjugation of Monoclonal Antibodies . . . . .  | 304        |
| 2.2 Flow Cytometric Analysis . . . . .  | 305        |
| 2.3 Radiolabeling. . . . .  | 305        |
| 2.4 Quality Control . . . . .   | 305        |

|      |   |     |
|------|---|-----|
| 2.5  | Cell Culture . . . . .  | 306 |
| 2.6  | Binding Saturation and Competitive Assays . . . . .   | 306 |
| 2.7  | Cytotoxicity Study . . . . .  | 306 |
| 2.8  | In Vivo Studies . . . . .   | 307 |
| 2.9  | Influence of Increasing Amount of BFC per mAb . . . . .   | 307 |
| 2.10 | Influence of the Nature of the Chelate on the In Vivo<br>Behavior of the Radioimmunoconjugate . . . . . | 307 |
| 2.11 | Biodistribution of $^{177}\text{Lu}$ -Nimotuzumab in Mice Bearing<br>SNU-C2B Xenograft . . . . .        | 307 |
| 2.12 | Biodistribution of $^{177}\text{Lu}$ -Nimotuzumab in Mice<br>Bearing A431 Xenograft . . . . .           | 308 |
| 2.13 | Statistical Analysis . . . . .  | 308 |
| 3    | Results and Discussion . . . . .  | 308 |
| 3.1  | Antibody Modification and Radiochemistry . . . . .  | 308 |
| 3.2  | In Vitro Studies . . . . .  | 310 |
| 3.3  | In Vivo Studies . . . . .   | 312 |
| 4    | Conclusion . . . . .  | 314 |
|      | References . . . . .  | 314 |

### Part III Molecular Imaging Using $^{68}\text{Ga}$ Labeled Tracers

|    |   |            |
|----|---|------------|
|    | <b>Divergent Role of <math>^{68}\text{Ga}</math>-Labeled Somatostatin Analogs in the<br/>Workup of Patients with NETs: AIIMS Experience . . . . .</b> | <b>321</b> |
| 1  | Introduction . . . . .  | 322        |
| 2  | Epidemiology . . . . .  | 323        |
| 3  | Our Study . . . . .   | 323        |
| 4  | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) . . . . .   | 323        |
| 5  | Classification . . . . .  | 324        |
| 6  | Functional Imaging of GEP-NETs . . . . .  | 325        |
| 7  | Studies with SRS (Somatostatin Receptor Scintigraphy) . . . . .   | 325        |
| 8  | Studies with $^{68}\text{Ga}$ -Labeled Octreotide Analogs . . . . .   | 326        |
| 9  | $^{68}\text{Ga}$ -DOTATOC/NOC Synthesis . . . . .   | 326        |
| 10 | $^{68}\text{Ga}$ -DOTA-Peptide Imaging Protocol . . . . .   | 326        |
| 11 | Normal Biodistribution of $^{68}\text{Ga}$ -Labeled Somatostatin Peptides . . . . .   | 327        |
| 12 | Sporadic GEP-NETs . . . . .   | 327        |
| 13 | Metastatic GEP-NETs with Occult/Uncertain Primary Tumor . . . . .   | 331        |
| 14 | Gastroenteropancreatic Neuroendocrine Tumors in Patients<br>with Hereditary Syndromes . . . . .   | 332        |
| 15 | Correlation of Tumor Uptake with Cellular Differentiation . . . . .   | 334        |
| 16 | Correlation of Tumor Uptake with SSSTR Subtypes . . . . .   | 335        |
| 17 | Impact on Management . . . . .  | 336        |
| 18 | Role of FDG-PET/CT . . . . .  | 337        |
| 19 | Pulmonary Neuroendocrine Tumors . . . . .   | 337        |



|    |  |     |
|----|--|-----|
| 20 | Medullary Carcinoma Thyroid. . . . .         | 338 |
| 21 | Pheochromocytoma and Paraganglioma . . . . . | 341 |
| 22 | Ectopic ACTH-Producing Tumors . . . . .      | 344 |
| 23 | Conclusions. . . . .                         | 346 |
|    | References . . . . .                         | 346 |

### **Differential Uptake of $^{68}\text{Ga}$ -DOTATOC and $^{68}\text{Ga}$ -DOTATATE**

|   |  |            |
|---|--|------------|
|   | <b>in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors . . . . .</b>     | <b>353</b> |
| 1 | Introduction. . . . .  | 355        |
| 2 | Patients and Methods . . . . .   | 356        |
|   | 2.1 Patients . . . . .   | 356        |
|   | 2.2 Radiopharmaceutical Preparation . . . . .                                  | 356        |
|   | 2.3 $^{68}\text{Ga}$ -DOTATOC and $^{68}\text{Ga}$ -DOTATATE Imaging . . . . . | 357        |
|   | 2.4 Image Evaluation . . . . .   | 357        |
|   | 2.5 Statistical Analysis . . . . .   | 358        |
| 3 | Results . . . . .  | 358        |
|   | 3.1 Regional and Lesional Analyses. . . . .                                    | 358        |
|   | 3.2 SUV Analyses . . . . .   | 362        |
| 4 | Discussion. . . . .  | 365        |
|   | 4.1 Lesion Detection . . . . .   | 365        |
|   | 4.2 Tumor Uptake . . . . .   | 366        |
|   | 4.3 Renal Uptake . . . . .   | 368        |
| 5 | Conclusion . . . . .   | 368        |
|   | References . . . . .   | 369        |

### **High Uptake of $^{68}\text{Ga}$ -DOTATOC in Spleen as Compared**

|   |   |            |
|---|---|------------|
|   | <b>to Splenosis: Measurement by PET/CT . . . . .</b>  | <b>373</b> |
| 1 | Introduction. . . . .                                 | 374        |
| 2 | Materials and Methods . . . . .                       | 374        |
| 3 | Results . . . . .                                     | 375        |
|   | 3.1 Initial Staging SSTR PET/CT . . . . .             | 375        |
|   | 3.2 Postpancreatectomy SSTR PET/CT Pre PRRNT. . . . . | 375        |
|   | 3.3 Restaging SSTR PET/CT Post PRRNT . . . . .        | 375        |
| 4 | Discussion. . . . .                                   | 376        |
| 5 | Conclusions. . . . .                                  | 377        |
|   | References . . . . .                                  | 378        |

### **Rare Metastases Detected by $^{68}\text{Ga}$ -Somatostatin Receptor PET/CT**

|   |   |            |
|---|---|------------|
|   | <b>in Patients with Neuroendocrine Tumors . . . . .</b> | <b>379</b> |
| 1 | Introduction. . . . .                                   | 380        |
| 2 | Prevalence and Location of Rare Metastases              |            |
|   | of Neuroendocrine Tumors . . . . .                      | 380        |
|   | 2.1 Cardiac Metastases . . . . .                        | 380        |
|   | 2.2 Breast Metastases . . . . .                         | 381        |

|     |  |     |
|-----|--|-----|
| 2.3 | Retro-Orbital . . . . .                        | 381 |
| 2.4 | Soft Tissue . . . . .                          | 382 |
| 2.5 | Uterus, Testes, and Seminal Vesicles . . . . . | 382 |
| 2.6 | Brain. . . . .                                 | 382 |
| 2.7 | Spleen. . . . .                                | 382 |
| 3   | Discussion. . . . .                            | 382 |
|     | References . . . . .                           | 384 |

### **Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma:**

|     |  |            |
|-----|--|------------|
|     | <b>Our Experience and a Review of the Literature . . . . .</b> | <b>385</b> |
| 1   | Introduction. . . . .  | 386        |
| 2   | Our Experience . . . . .                                       | 387        |
| 2.1 | Patients . . . . .   | 387        |
| 2.2 | PET/CT Protocol and Data Analysis . . . . .                    | 387        |
| 2.3 | Statistical Analysis . . . . .                                 | 388        |
| 2.4 | Results . . . . .  | 388        |
| 3   | Literature Review . . . . .                                    | 389        |
| 4   | Discussion. . . . .  | 389        |
| 5   | Conclusion . . . . .   | 391        |
|     | References . . . . .   | 392        |

### **PET Lung Ventilation/Perfusion Imaging Using $^{68}\text{Ga}$ Aerosol (Galligas) and $^{68}\text{Ga}$ -Labeled Macroaggregated Albumin . . . . .**

|     |   |            |
|-----|---|------------|
|     |   | <b>395</b> |
| 1   | Introduction. . . . .   | 397        |
| 1.1 | Background . . . . .  | 397        |
| 1.2 | Objective. . . . .  | 398        |
| 2   | Materials and Methods . . . . .   | 399        |
| 2.1 | Materials . . . . .   | 399        |
| 2.2 | Methods . . . . .   | 399        |
| 2.3 | Exploratory Studies. . . . .  | 401        |
| 3   | Results . . . . .   | 403        |
| 3.1 | $^{68}\text{Ga}$ -Labeled Human Serum Albumin Microspheres. . . . .                           | 403        |
| 3.2 | Exploratory Studies. . . . .  | 403        |
| 3.3 | Dosimetry . . . . .   | 406        |
| 4   | Discussion. . . . .   | 411        |
| 4.1 | $^{68}\text{Ga}$ -Labeled Radiotracer for Lung Ventilation<br>and Perfusion Imaging . . . . . | 411        |
| 4.2 | Dosimetry . . . . .   | 419        |
| 4.3 | Perspectives . . . . .  | 421        |
|     | References . . . . .  | 422        |

|   |            |
|---|------------|
| <b>Combined PET/MR Imaging Using <math>^{68}\text{Ga}</math>-DOTATOC for Radiotherapy Treatment Planning in Meningioma Patients . . . . .</b> | <b>425</b> |
| 1 Introduction . . . . .  | 427        |
| 2 Methods . . . . .   | 429        |
| 2.1 PET/MR Tomography . . . . .   | 429        |
| 2.2 Diagnosis and RT Treatment Planning of Meningioma . . . . .   | 430        |
| 2.3 $^{68}\text{Ga}$ -DOTATOC PET/MR Protocol . . . . .   | 431        |
| 2.4 Radiotherapy Treatment Planning . . . . .   | 432        |
| 2.5 Clinical Examples . . . . .   | 432        |
| 3 Discussion . . . . .  | 435        |
| 4 Conclusion . . . . .  | 437        |
| References . . . . .  | 438        |

#### **Part IV Targeted Radiotherapy (Peptide Receptor Radionuclide Therapy) and Dosimetry**

|   |            |
|---|------------|
| <b>A Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign . . . . .</b> | <b>443</b> |
| 1 Case Presentation . . . . .   | 444        |
| 1.1 Clinical Findings . . . . .   | 444        |
| 1.2 Histology and Genetic Analyses . . . . .  | 445        |
| 1.3 Pretherapeutic Imaging . . . . .  | 445        |
| 1.4 Therapy . . . . .   | 446        |
| 2 Discussion . . . . .  | 447        |
| References . . . . .  | 453        |

|   |            |
|---|------------|
| <b>Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry . . . . .</b> | <b>457</b> |
| 1 Introduction . . . . .  | 458        |
| 2 Patients and Methods . . . . .  | 459        |
| 3 Results . . . . .   | 460        |
| 4 Discussion . . . . .  | 462        |
| References . . . . .  | 464        |

|   |            |
|---|------------|
| <b>Polish Experience in Peptide Receptor Radionuclide Therapy . . . . .</b> | <b>467</b> |
| 1 Introduction . . . . .  | 469        |
| 2 Materials and Methods . . . . .   | 469        |
| 2.1 Radiopharmaceuticals . . . . .  | 471        |
| 2.2 Treatment Procedure . . . . .   | 471        |
| 2.3 Evaluation of Results and Assessment of Clinical Benefit . . . . .      | 472        |
| 3 Results . . . . .   | 472        |

|     |  |            |
|-----|--|------------|
| 3.1 | Side-Effects of Treatment . . . . .  | 474        |
| 4   | Discussion. . . . .  | 475        |
| 5   | Conclusions. . . . .   | 476        |
|     | References . . . . .   | 476        |
|     | <b>PRRT as Neoadjuvant Treatment in NET . . . . .</b>  | <b>479</b> |
| 1   | Introduction. . . . .  | 480        |
| 2   | Methods and Results . . . . .  | 481        |
| 3   | Conclusion . . . . .   | 484        |
|     | References . . . . .   | 485        |
|     | <b>Intraoperative Somatostatin Receptor Detection After Peptide<br/>Receptor Radionuclide Therapy with <math>^{177}\text{Lu}</math>- and <math>^{90}\text{Y}</math>-DOTATOC<br/>(Tandem PRRNT) in a Patient with a Metastatic<br/>Neuroendocrine Tumor . . . . .</b> | <b>487</b> |
| 1   | Introduction. . . . .  | 489        |
| 2   | Materials and Methods . . . . .  | 490        |
| 3   | Results . . . . .  | 490        |
| 4   | Discussion and Conclusions . . . . .   | 495        |
|     | References . . . . .   | 496        |
|     | <b>Personalized Image-Based Radiation Dosimetry for Routine<br/>Clinical Use in Peptide Receptor Radionuclide Therapy:<br/>Pretherapy Experience . . . . .</b>   | <b>497</b> |
| 1   | Introduction. . . . .  | 498        |
| 2   | Challenges in Patient-Specific Dosimetry<br>for Radionuclide Therapy . . . . .   | 499        |
| 3   | General Concepts in Internal Dosimetry . . . . .   | 501        |
| 4   | Key Elements of Internal Dose Calculations . . . . .   | 502        |
| 4.1 | Imaging Protocol . . . . .   | 502        |
| 4.2 | Image Reconstruction . . . . .   | 504        |
| 4.3 | Segmentation of Nuclear Medicine Images . . . . .  | 505        |
| 4.4 | Dose Calculation Method . . . . .  | 506        |
| 4.5 | Software Tools for Dosimetry Calculations . . . . .  | 507        |
| 5   | Clinical Implementation of the Proposed Dose<br>Calculation Technique . . . . .  | 509        |
| 5.1 | Patient Image Acquisition . . . . .  | 510        |
| 5.2 | Phantom Experiments to Calibrate Parameters<br>for the Adaptive Threshold Technique . . . . .  | 510        |
| 5.3 | Data Processing . . . . .  | 511        |
| 5.4 | Dosimetry Results . . . . .  | 512        |
| 5.5 | Therapy. . . . .   | 513        |
| 6   | Conclusions. . . . .   | 514        |
|     | References . . . . .   | 515        |

## **The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using**

|  |            |
|--|------------|
| <b><math>^{177}\text{Lu}</math>-DOTATATE, <math>^{177}\text{Lu}</math>-DOTANOC, and <math>^{177}\text{Lu}</math>-DOTATOC . . . . .</b> | <b>519</b> |
| 1 Introduction. . . . .  | 520        |
| 2 Patients and Methods . . . . .   | 521        |
| 2.1 Patients . . . . .   | 521        |
| 2.2 Radiopharmaceuticals . . . . .   | 523        |
| 2.3 Infusion and Renal Protection . . . . .  | 523        |
| 2.4 Dosimetry . . . . .  | 523        |
| 2.5 Comparison and Statistics . . . . .  | 524        |
| 3 Results . . . . .  | 525        |
| 3.1 Normal Organs. . . . .   | 525        |
| 3.2 Tumor Lesions. . . . .   | 529        |
| 3.3 Tumor-to-Kidney Ratio. . . . .   | 530        |
| 3.4 Variability . . . . .  | 530        |
| 4 Discussion. . . . .  | 531        |
| 5 Conclusions. . . . .   | 534        |
| References . . . . .   | 535        |

## **4D SPECT/CT Acquisition for 3D Dose Calculation and Dose Planning in $^{177}\text{Lu}$ -Peptide Receptor Radionuclide Therapy:**

|  |            |
|--|------------|
| <b>Applications for Clinical Routine . . . . .</b> | <b>537</b> |
| 1 Introduction and Background Information. . . . . | 538        |
| 2 Methods and Materials . . . . .                  | 540        |
| 2.1 Dose Calculation . . . . .                     | 540        |
| 2.2 Clinical Practice. . . . .                     | 542        |
| 3 Results . . . . .                                | 543        |
| 4 Discussion. . . . .                              | 546        |
| 5 Conclusions and Summary of the Results . . . . . | 549        |
| References . . . . .                               | 549        |

## **Peptide Receptor Radionuclide Therapy with $^{177}\text{Lu}$ Labeled Somatostatin Analogs DOTATATE and DOTATOC:**

|  |            |
|--|------------|
| <b>Contrasting Renal Dosimetry in the Same Patient . . . . .</b> | <b>551</b> |
| 1 Introduction. . . . .  | 552        |
| 2 Patients and Methods . . . . .                                 | 553        |
| 2.1 Patients . . . . .   | 553        |
| 2.2 Radiopharmaceuticals . . . . .                               | 553        |
| 2.3 Infusion and Renal Protection . . . . .                      | 554        |
| 2.4 Monitoring of Renal Function . . . . .                       | 554        |
| 2.5 Dosimetry . . . . .  | 554        |
| 2.6 Comparison and Statistics . . . . .                          | 555        |
| 3 Results . . . . .  | 555        |
| 4 Discussion. . . . .  | 556        |

|   |                      |     |
|---|----------------------|-----|
| 5 | Conclusions. . . . . | 558 |
|   | References . . . . . | 558 |

**Is There a Correlation Between Peptide Receptor Radionuclide  
Therapy-Associated Hematological Toxicity and Spleen Dose? . . . . . 561**

|     |                                |     |
|-----|--------------------------------|-----|
| 1   | Background. . . . .            | 562 |
| 2   | Patients and Methods . . . . . | 563 |
| 2.1 | Patients . . . . .             | 563 |
| 2.2 | Dosimetry . . . . .            | 563 |
| 2.3 | Statistics . . . . .           | 563 |
| 3   | Results . . . . .              | 565 |
| 4   | Conclusion . . . . .           | 565 |
|     | References . . . . .           | 566 |

**Old and New Peptide Receptor Targets in Cancer:  
Future Directions . . . . . 567**

|   |                                 |     |
|---|---------------------------------|-----|
| 1 | Introduction. . . . .           | 568 |
| 2 | Somatostatin Receptors. . . . . | 569 |
| 3 | Bombesin Receptors. . . . .     | 570 |
| 4 | Incretin Receptors . . . . .    | 573 |
| 5 | Conclusion . . . . .            | 574 |
|   | References . . . . .            | 574 |

Theranostics, Gallium-68, and Other Radionuclides  
A Pathway to Personalized Diagnosis and Treatment

Baum, R.P.; Rösch, F. (Eds.)

2013, XVIII, 578 p., Hardcover

ISBN: 978-3-642-27993-5